Objectives and methods: YC-20 is a novel oxazolidinone that has targeted activity against Gram-positive bacteria. The in vitro activity of YC-20 and 6 comparators against 522 clinical isolates of Gram-positive species was determined.
Introduction
A rapid expansion of antimicrobial resistance has led to the development of new antimicrobial agents. Oxazolidinones are a new class of totally synthetic antimicrobial agents active against multidrug-resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant Enterococcus (VRE). 1, 2 Linezolid (see Figure 1 ), the first commercially available oxazolidinone, showed a broad activity against Gram-positive bacteria. 3, 4 During our research work on antibacterial agents, YC-20 (see Figure 1 ) was found to be a new oxazolidinone with enhanced activity against Gram-positive organisms. 5 The present study examines the in vitro antibacterial activity of YC-20 by comparing the MIC 50 and MIC 90 values with those obtained for linezolid, vancomycin, ampicillin, cefazolin, clarithromycin and levofloxacin against 522 isolates.
Materials and methods
Inclusion criteria: all microbiological samples between 2002 and 2003 were selected. Microscopy and culture data as well as susceptibility test results were analysed. A total of 522 strains were collected and identified at Sichuan Industrial Institute of Antibiotics by routine methodologies in use.
Antimicrobial susceptibility testing was performed using broth microdilution methods as described by the National Committee for Clinical Laboratory Standards (NCCLS). 6 Linezolid was prepared as described previously. 7 Other antimicrobial agents (vancomycin, ampicillin, cefazolin, clarithromycin and levofloxacin) were purchased from the National Institute for Control of Pharmaceutical and Biological Products. A total of 522 isolates were collected, comprising 200 S. aureus, 210 S. epidermidis, 20 Staphylococcus haemolyticus, 30 group A Streptococcus, 22 S. pneumoniae and 40 vancomycin-susceptible Enterococcus. Quality control measures were utilized by concurrently testing S. aureus ATCC 25923 and ATCC 29213.
Results
Results of microdilution MIC testing of the 522 isolates are presented in Table 1 .
The For isolates of S. pneumoniae, MICs ranged from 0.125 to 0.5 mg/L for penicillin-susceptible strains compared with 0.25 to 4 mg/L for penicillin-resistant strains. MICs of YC-20 were two or four dilutions lower than those of linezolid. Activity of YC-20 against S. pneumoniae was weaker than that of vancomycin.
YC-20 was also active against group A streptococcal isolates with MICs of YC-20 being four dilutions lower than those of linezolid.
The MIC ranges observed for YC-20 and linezolid for vancomycin-susceptible Enterococcus were similar (0.25 to 0.5 mg/L). 
